2Xideas AG Has $44.30 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

2Xideas AG lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 14.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 225,423 shares of the medical research company’s stock after buying an additional 28,624 shares during the quarter. IQVIA comprises approximately 5.9% of 2Xideas AG’s investment portfolio, making the stock its 4th largest holding. 2Xideas AG owned about 0.12% of IQVIA worth $44,298,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Synergy Asset Management LLC bought a new position in IQVIA in the fourth quarter worth approximately $33,000. Lee Danner & Bass Inc. acquired a new position in shares of IQVIA during the fourth quarter worth approximately $44,000. Zions Bancorporation N.A. lifted its holdings in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after purchasing an additional 85 shares in the last quarter. Versant Capital Management Inc grew its position in IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. bought a new stake in IQVIA during the 4th quarter valued at $60,000. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on IQV shares. Bank of America reduced their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a report on Friday, December 13th. William Blair reissued an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Truist Financial reiterated a “buy” rating and set a $263.00 price target (up previously from $261.00) on shares of IQVIA in a report on Monday, February 10th. Finally, Robert W. Baird dropped their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Price Performance

Shares of NYSE IQV opened at $154.63 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a fifty day simple moving average of $189.67 and a two-hundred day simple moving average of $203.82. IQVIA Holdings Inc. has a 1-year low of $154.35 and a 1-year high of $252.88. The firm has a market cap of $27.26 billion, a price-to-earnings ratio of 20.62, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.